(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued ...
GSK GSK0.69%increase ... index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine ...
GSK) soared over 6% after the company announced a settlement of up to $2.2 billion for Zantac lawsuits in the U.S. The settlement addresses 80,000 cases, accounting for 93% of the pending lawsuits ...
Tens of thousands of Zantac users have filed product liability lawsuits against GSK and other makers ... The company said it had also agreed to pay $70 million to settle a whistle-blower complaint ...
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...
GSK said late Wednesday that it agreed to settle a vast majority of lawsuits concerning its discontinued heartburn medicine Zantac. "GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement," at ...
or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer ...
Oct 9 (Reuters) - GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company ...
GSK shares top the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed ... to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac ...